NuvOx Expands Production LineNuvOx PharmaDec 7, 20191 min readNuvOx Pharma is breaking ground on an addition to its manufacturing facility.Read full story
NuvOx Announces First Patient Dosed for its EXTEND trials: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II TrialsTucson, AZ – June 12, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been dosed for its EXTEND trials :...
NIH Panel - Commercializing SBIR/STTR TechnologiesFeaturing Co-Founder and Executive Chairman Dr. Evan Unger As Panelist in Commercializing SBIR/STTR Technologies Discussion at 2025 BIO...
NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial InfarctionNuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction Tucson, AZ – March 4, 2025 - NuvOx...
Comments